Pulmonary Cavitary Disease Secondary to Mycobacterium xenopi Complicated by Respiratory Failure
- PMID: 30648049
- PMCID: PMC6318116
- DOI: 10.7759/cureus.3512
Pulmonary Cavitary Disease Secondary to Mycobacterium xenopi Complicated by Respiratory Failure
Abstract
Non-tuberculous mycobacteria (NTM) are a significant cause of pulmonary infection worldwide and can be clinically challenging. Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment, as in the case of a human immunodeficiency virus infection, or a structural lung disease to cause a clinical disease. Comorbidities have an essential role in M. xenopi occurrence. Herein, we present a rare case of pulmonary cavitary disease caused by M. xenopi complicated by respiratory failure and superinfection in a patient with a chronic obstructive pulmonary disease. An 81-year-old woman presented to the hospital with the chief concerns of shortness of breath and productive cough lasting a few weeks before presentation. A computed tomography scan of the chest showed a right upper lobe, thick-walled, cavitary lesion measuring 2.1 cm x 4.3 cm x 3.1 cm with associated bronchiectasis and pleural parenchymal scarring. One year ago, the patient underwent bronchoscopy for a right upper lobe cavitary lesion, which revealed M. xenopi on bronchoalveolar lavage culture. During the current admission, she was started on rifampin, isoniazid, ethambutol, and clarithromycin because the M. xenopi was clinically significant and fulfilled the American Thoracic Society diagnostic criteria for NTM lung disease. A diagnosis of NTM pulmonary disease does not necessarily suggest that treatment is required. The distinction between colonization and illness may be difficult upon the isolation of M. xenopi. A patient-centered approach is essential given that M. xenopi is often considered a commensal pathogen. When treatment is required, a multidrug approach with an individualized, optimal duration of therapy should be considered.
Keywords: copd; mycobacterium xenopi; non-tuberculous mycobacteria; pulmonary cavitary disease; respiratory failure.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
Pulmonary cavitary disease due to Mycobacterium xenopi.Infect Med (Beijing). 2022 Jan 1;1(1):63-66. doi: 10.1016/j.imj.2021.11.001. eCollection 2022 Mar. Infect Med (Beijing). 2022. PMID: 38074974 Free PMC article.
-
Navigating a Complex Case of Mycobacterium Xenopi in a Patient with Blue Rubber Bleb Nevus Syndrome.Eur J Case Rep Intern Med. 2024 May 2;11(6):004530. doi: 10.12890/2024_004530. eCollection 2024. Eur J Case Rep Intern Med. 2024. PMID: 38846651 Free PMC article.
-
Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis.J Community Hosp Intern Med Perspect. 2017 Dec 14;7(6):372-377. doi: 10.1080/20009666.2017.1407211. eCollection 2017. J Community Hosp Intern Med Perspect. 2017. PMID: 29296252 Free PMC article.
-
[Four cases of Mycobacterium xenopi pulmonary disease].Kekkaku. 2004 Apr;79(4):313-20. Kekkaku. 2004. PMID: 15168439 Review. Japanese.
-
Update on pulmonary disease due to non-tuberculous mycobacteria.Int J Infect Dis. 2016 Apr;45:123-34. doi: 10.1016/j.ijid.2016.03.006. Epub 2016 Mar 11. Int J Infect Dis. 2016. PMID: 26976549 Review.
Cited by
-
Pulmonary cavitary disease due to Mycobacterium xenopi.Infect Med (Beijing). 2022 Jan 1;1(1):63-66. doi: 10.1016/j.imj.2021.11.001. eCollection 2022 Mar. Infect Med (Beijing). 2022. PMID: 38074974 Free PMC article.
-
Novel case of empyema necessitans caused by Mycobacterium xenopi.BMJ Case Rep. 2022 May 12;15(5):e245953. doi: 10.1136/bcr-2021-245953. BMJ Case Rep. 2022. PMID: 35550319 Free PMC article.
-
A Computational Approach to Repurposing Natural Products for DprE1 Inhibition.Scientifica (Cairo). 2025 Jul 9;2025:2105236. doi: 10.1155/sci5/2105236. eCollection 2025. Scientifica (Cairo). 2025. PMID: 40678077 Free PMC article.
-
Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients.Clin Pract. 2021 Sep 9;11(3):619-630. doi: 10.3390/clinpract11030077. Clin Pract. 2021. PMID: 34563006 Free PMC article. Review.
-
Non-tuberculous mycobacterial lung disease: a brief review focusing on radiological findings.Rev Soc Bras Med Trop. 2020 Sep 11;53:e20200241. doi: 10.1590/0037-8682-0241-2020. eCollection 2020. Rev Soc Bras Med Trop. 2020. PMID: 32935786 Free PMC article. Review.
References
-
- Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi. Carrillo MC, Patsios D, Wagnetz U, Jamieson F, Marras TK. Can Assoc Radiol J. 2014;65:207–213. - PubMed
-
- Microbiological and clinical outcomes of treating non-mycobacterium avium complex nontuberculous Mycobacterial pulmonary disease: a systematic review and meta-analysis. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J, Nienhaus A. Chest. 2017;152:120–142. - PubMed
-
- An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Griffith DE, Aksamit T, Brown-Elliott BA, et al. Am J Respir Crit Care Med. 2007;175:367–416. - PubMed
-
- Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997;156:1–25. - PubMed
Publication types
LinkOut - more resources
Full Text Sources